Year: 2012

Frailty & Muscle Loss Increase Mortality & Are Common in HIV+

Subject: NATAP/CROI: Frailty/Muscle Loss in HIV Increases Mortality & is Common NATAP https://natap.org/ _______________________________________________ Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ from Jules Levin at CROI Live in Seattle. This poster session is a breakthrough in that it is identifying that muscle loss & frailty are fairly common in HIV+ persons & they …

Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ Read More »

Pre-CROI HIV Cure Review Workshop Organized by Community Advocates- Meeting Notes

Thanks to Siegfried Schwarze, a research activist from  Germany, for writing down these notes from the meeting we had this past Sunday, March 4, 2012 in Seattle prior to CROI-2012. **************************************************************************** Sometimes the most important events don‘t take place at the conference itself but rather at  the surrounding workshops. This seemed to be the case this …

Pre-CROI HIV Cure Review Workshop Organized by Community Advocates- Meeting Notes Read More »

Report of This Weekend’s HIV Cure Workshop in Seattle

A couple of months ago a rag tag group of activist–including Project Inform (represented by myself), the Treatment Action Group (TAG) and the AIDS Treatment Activists Coalition (ATAC)–reached out to some of the world’s leading HIV researchers and companies working on HIV cure research and asked them to spend an entire day with us talking …

Report of This Weekend’s HIV Cure Workshop in Seattle Read More »

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse

The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare’s investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for …

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse Read More »

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program

FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel (NelsonVergel@yahoo.com) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing  expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with …

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program Read More »

What to do if you think you have recently been exposed to HIV

This would definitely be the HIV medication combo that I would take if I was HIV negative and wanted to treat a potential HIV exposure (condom breakage, needle stick, etc). Prior studies were done using Truvada alone (two drugs combined in one pill), but adding raltegravir to Truvada makes a lot of sense. Raltegravir (brand …

What to do if you think you have recently been exposed to HIV Read More »

Outsmarting HIV with Healthy Nutrition

From: https://www.positivelyaware.com/2012/12_01/hiv_wellness_series.shtml Living with a chronic illness like HIV can present certain nutritional challenges. Without effective HIV medication treatment, replicating virus can tax the body, destroying lean body mass and impairing immune function and quality of life.1, 2 While this destruction of lean tissue can be controlled with effective HIV antiretroviral combination therapy, other challenges like fat …

Outsmarting HIV with Healthy Nutrition Read More »